Tag Archives: Sclerosis

FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis

FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis Print this page CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved Vumerity (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for… Read More »

Creating a Detailed Genetic Map of Multiple Sclerosis

Researchers at the John P. Hussman Institute for Human Genomics, led by Jacob L. McCauley, Ph.D., and Margaret A. Pericak-Vance, Ph.D., have completed a study creating a detailed genetic map of multiple sclerosis. Their study, “Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility,” was recently published in the journal Science. MS is… Read More »

FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)

Print this page September 06, 2019 — The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition. “Patients suffering from… Read More »

Novartis’s Sandoz licenses proposed multiple sclerosis biosimilar

ZURICH (Reuters) – Swiss drugmaker Novartis’s Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord. The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Polpharma Biologics will develop, manufacture… Read More »

FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis

FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis Print this page March 29, 2019 — The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease. Mavenclad is not recommended for MS patients with clinically isolated… Read More »